Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 anti-CD 22 chimeric antigen receptor T cell therapy - Chongqing Precision Biotech

Next Previous
X
Search
Drug Profile

Anti-CD19 anti-CD 22 chimeric antigen receptor T cell therapy - Chongqing Precision Biotech

Alternative Names: Anti-CD19/Anti-CD22 CAR-T cell therapy-Chongqing Precision Biotech; CD19/CD22 dual CAR-T- Chongqing Precision Biotech

Latest Information Update: 09 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chongqing Precision Biotech Co., Ltd
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B-cell lymphoma; Leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 23 May 2021 Chongqing Precision Biotech initiates a phase I/II trial for B-cell lymphoma (In children, In adults, In adolescents, In the elderly, Second-line therapy or greater) in China (IV) (NCT04782193)
  • 01 Jan 2021 Phase-I/II clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (In adolescents, In adults, In children, In the elderly, Second-line therapy or greater) in China (IV) (NCT04781634)
  • 25 Aug 2020 Phase-I/II clinical trials in B-cell lymphoma (In children, In adults, In adolescents, In the elderly, Second-line therapy or greater) in China (IV) (NCT04648475)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top